scholarly journals Assessment of safety and effectiveness for pediatric patients of cryoanalgesia compared to epidural for the Nuss procedure in real-world data from Electronic Health Records: a protocol and statistical analysis plan v1 (protocols.io.bbpaimie)

protocols.io ◽  
2020 ◽  
Author(s):  
Benjamin S ◽  
Roberto Mora ◽  
Stefano Rensi ◽  
Vivek A ◽  
Andrew M ◽  
...  
2018 ◽  
Vol 24 (3) ◽  
pp. 95-98 ◽  
Author(s):  
Daphne Guinn ◽  
Erin E Wilhelm ◽  
Grazyna Lieberman ◽  
Sean Khozin

2020 ◽  
Vol 107 (4) ◽  
pp. 934-943 ◽  
Author(s):  
Leena Choi ◽  
Cole Beck ◽  
Elizabeth McNeer ◽  
Hannah L. Weeks ◽  
Michael L. Williams ◽  
...  

2017 ◽  
pp. 1-11 ◽  
Author(s):  
Jan R.R. Lewis ◽  
Ian Kerridge ◽  
Wendy Lipworth

Although randomized controlled trials remain the scientific ideal for determining the efficacy and safety of new treatments, they are sometimes insufficient to address the evidentiary requirements of regulators and payers. This is particularly the case when it comes to precision medicines because trials are often small, deliver incomplete insights into outcomes of most interest to policymakers (eg, overall survival), and may fail to address other complex diagnostic and treatment-related questions. Additional methods, both experimental and observational, are increasingly being used to fill critical evidentiary gaps. A number of modified early- and late-phase trial designs have been proposed to better support earlier biomarker validation, patient identification, and selection for regulatory studies, but there is still a need for confirmatory evidence from real-world data sources. These data are usually provided through observational, postapproval, phase IIIB and IV studies, which rely heavily on registries and other electronic data sets—most notably data from electronic health records. It is, therefore, crucial to understand what ethical, practical, and scientific challenges are raised by the use of electronic health records to generate evidence about precision medicines.


Nature Cancer ◽  
2021 ◽  
Vol 2 (7) ◽  
pp. 709-722 ◽  
Author(s):  
Olivier Morin ◽  
Martin Vallières ◽  
Steve Braunstein ◽  
Jorge Barrios Ginart ◽  
Taman Upadhaya ◽  
...  

Author(s):  
James R Rogers ◽  
Junghwan Lee ◽  
Ziheng Zhou ◽  
Ying Kuen Cheung ◽  
George Hripcsak ◽  
...  

Abstract Objective Real-world data (RWD), defined as routinely collected healthcare data, can be a potential catalyst for addressing challenges faced in clinical trials. We performed a scoping review of database-specific RWD applications within clinical trial contexts, synthesizing prominent uses and themes. Materials and Methods Querying 3 biomedical literature databases, research articles using electronic health records, administrative claims databases, or clinical registries either within a clinical trial or in tandem with methodology related to clinical trials were included. Articles were required to use at least 1 US RWD source. All abstract screening, full-text screening, and data extraction was performed by 1 reviewer. Two reviewers independently verified all decisions. Results Of 2020 screened articles, 89 qualified: 59 articles used electronic health records, 29 used administrative claims, and 26 used registries. Our synthesis was driven by the general life cycle of a clinical trial, culminating into 3 major themes: trial process tasks (51 articles); dissemination strategies (6); and generalizability assessments (34). Despite a diverse set of diseases studied, <10% of trials using RWD for trial process tasks evaluated medications or procedures (5/51). All articles highlighted data-related challenges, such as missing values. Discussion Database-specific RWD have been occasionally leveraged for various clinical trial tasks. We observed underuse of RWD within conducted medication or procedure trials, though it is subject to the confounder of implicit report of RWD use. Conclusion Enhanced incorporation of RWD should be further explored for medication or procedure trials, including better understanding of how to handle related data quality issues to facilitate RWD use.


Author(s):  
Sarah Riepenhausen ◽  
Cornelia Mertens ◽  
Martin Dugas

Real world data for use in clinical trials is promising. We compared the SDTM for clinical trial data submission with FHIR® for routine documentation. After categorization of variables by relevance, clinically relevant SDTM items were mapped to FHIR®. About 30% in both were seen as clinically relevant. The majority of these SDTM items were mappable to FHIR® Observation resource.


Sign in / Sign up

Export Citation Format

Share Document